Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 BV100 plus low-dose polymyxin B versus colistin plus high-dose ampicillin/sulbactam for carbapenem-resistant Acinetobacter hospital- or ventilator-associated bacterial pneumonia
MOH_2026-04-13_015762Phase 3Not yet recruiting
- Sponsor
- BioVersys AG
- Start
- Feb 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of BV100 and polymyxin B, sponsored by BioVersys AG. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
BV100polymyxin B
Beyond the preview
Go deeper on MOH_2026-04-13_015762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-13_015762.